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ABSTRACT Vaccines play a crucial role in the protection of animals and humans
from deadly pathogens. The ﬁrst vaccine that also protected against cancer was de-
veloped against the highly oncogenic herpesvirus Marek’s disease virus (MDV). MDV
infects chickens and causes severe immunosuppression, neurological signs, and fatal
lymphomas, a process that requires the viral oncogene, meq. The most frequently
used Marek’s disease vaccine is the live-attenuated CVI988/Rispens (CVI) strain,
which efﬁciently protects chickens and prevents tumorigenesis. Intriguingly, CVI ex-
presses at least two isoforms of meq; however, it remains unknown to what extent
these isoforms contribute to virus attenuation. In this study, we individually exam-
ined the contribution of the two CVI-meq isoforms to the attenuation of the vaccine.
We inserted the respective isoforms into a very virulent MDV (strain RB-1B), thereby
replacing its original meq gene. Surprisingly, we could demonstrate that the longer
isoform of meq strongly enhanced virus-induced pathogenesis and tumorigenesis,
indicating that other mutations in the CVI genome contribute to virus attenuation.
On the contrary, the shorter isoform completely abrogated pathogenesis, demon-
strating that changes in the meq gene can indeed play a key role in virus attenua-
tion. Taken together, our study provides important evidence on attenuation of one
of the most frequently used veterinary vaccines worldwide.
IMPORTANCE Marek’s disease virus (MDV) is one of several oncogenic herpesviruses
and causes fatal lymphomas in chickens. The current “gold standard” vaccine is the
live-attenuated MDV strain CVI988/Rispens (CVI), which is widely used and efﬁciently
prevents tumor formation. Intriguingly, CVI expresses two predominant isoforms of
the major MDV oncogene meq: one variant with a regular size of meq (Smeq) and
one long isoform (Lmeq) harboring an insertion of 180 bp in the transactivation do-
main. In our study, we could break the long-standing assumption that the Lmeq
isoform is an indicator for virus attenuation. Using recombinant viruses that ex-
press the different CVI-meq isoforms, we could demonstrate that both isoforms
drastically differ in their abilities to promote pathogenesis and tumor formation
in infected chickens.
KEYWORDS vaccine, CVI988/Rispens, Marek’s disease virus (MDV), tumorigenesis, T
cell lymphoma, cancer, meq gene, basic leucine zipper (bZIP) protein, herpesvirus
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Marek’s disease virus (MDV) is a lymphotropic alphaherpesvirus that infects chick-ens and causes 1 to 2 billion dollar losses worldwide annually (1). MDV causes a
variety of clinical symptoms, including immunosuppression, ataxia, chronic wasting,
and formation of T cell lymphoma in various visceral organs (2). MDV vaccines are
widely used to protect chickens from this deadly disease and were the ﬁrst vaccines
that prevented cancer, long before this approach was applied to human medicine (3,
4). The current “gold standard” vaccine is the live-attenuated MDV strain, CVI988/
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Rispens (CVI), which efﬁciently protects chickens against very virulent ﬁeld strains (5, 6).
Intriguingly, commercial vaccine stocks express two predominant isoforms of the major
MDV oncogene meq (7). The Meq protein is a basic leucine zipper (bZIP) protein that
is essential for tumorigenesis, represses apoptosis, dysregulates the cell cycle, and
modulates cellular and viral gene expression (8–10). One of the cellular targets is c-myc,
which inﬂuences the expression of MDV-encoded viral telomerase RNA (vTR) (11), a
noncoding RNA that plays an important role in tumorigenesis (12). One of the two
CVI-carried meq genes has the same size as its counterparts in virulent MDV strains, but
harbors several point mutations (Smeq) (Fig. 1A) (13). The other isoform is identical to
Smeq except for an in-frame insertion (Lmeq) of 180 bp (60 amino acids) in the
carboxy-terminal transactivation domain (14, 15). The insertion consists of proline-rich
repeats (PRR) that likely arose from a domain duplication (16). It has been shown that
these two CVI-meqs are weak transactivators of viral gene expression, which could
contribute to the nononcogenic phenotype of the CVI virus in chickens (7). To deter-
mine the role of the meq isoforms expressed in the CVI vaccine, we replaced the meq
gene in the very virulent MDV strain RB-1B with either the Smeq (vSmeq) or Lmeq
(vLmeq) isoform. Intriguingly, we found that viruses with these vaccine-derived meq
isoforms strikingly differ in pathogenesis and oncogenesis in infected chickens.
RESULTS
Generation of recombinant viruses. To examine the contribution of the two meq
isoforms in the attenuation of the CVI vaccine, we generated recombinant viruses that
FIG 1 Construction and in vitro characterization of recombinant viruses. (A) Schematic representation of the MDV RB-1B
genome with a focus on the different meq genes, including mutations in the basic domain and proline-rich repeats. (B)
Virus spread was assessed by plaque size assays (n 150) and replication by (C) multistep growth kinetics 1 to 6 days
postinfection. Spread and replication of indicated recombinant viruses were not statistically different (P 0.05, one-way
ANOVA). (D) meq expression levels in infected chicken embryo cells relative to GAPDH were not statistically different (P 
0.05, Kruskal-Wallis test). Data are shown as the means from a minimum of three independent experiments with standard
deviation (SD [shown by error bars]).
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harbor either the Smeq or Lmeq isoform. CVI-meq isoforms were individually inserted
into the very virulent RB-1B MDV strain instead of its native meq gene (Fig. 1A). We
conﬁrmed the resulting clones with PCR, restriction fragment length polymorphism
(RFLP), Sanger sequencing, and Illumina MiSeq whole-genome sequencing with an
1,000-fold coverage to conﬁrm the integrity and the sequence of the entire virus
genome.
In vitro characterization of recombinant viruses. To determine if insertion of the
meq isoforms affects virus replication, we performed plaque size assays and examined
multistep growth kinetics. We could demonstrate that the recombinant viruses efﬁ-
ciently replicate similar to the parental (wild-type) virus (Fig. 1B and C), indicating that
the insertion of the CVI-meq isoforms in a very virulent RB-1B strain does not affect virus
replication in vitro. To ensure that both CVI-meq isoforms are efﬁciently expressed, we
quantiﬁed the expression levels of meq in virus-infected cells by quantitative reverse
transcription-PCR (RT-qPCR). We could demonstrate that the meq gene expression of
vSmeq or vLmeq was comparable to themeq expression in the wild-type virus (Fig. 1D).
Replication of recombinant viruses in vivo. To assess if the CVI-meq isoforms
affect virus replication, pathogenesis, and/or tumor formation in vivo, we infected
1-day-old Valo speciﬁc-pathogen-free (SPF) chickens subcutaneously with 4,000 PFU of
wild-type virus, vSmeq, or vLmeq. The viral load in the blood was assessed by qPCR and
revealed that the recombinant viruses replicated efﬁciently in infected animals (Fig. 2A),
indicating that the CVI-meq isoforms do not affect virus replication in vivo. Moreover, all
viruses efﬁciently spread to cohoused contact chickens, conﬁrming that the insertion of
Smeq and Lmeq did not signiﬁcantly inﬂuence virus transmission to naive contact
chickens (Fig. 2B).
Pathogenesis and tumorigenesis of recombinant viruses in vivo. We monitored
the animals for clinical symptoms and tumor development over the course of the
experiment. The recombinant virus harboring the Smeq isoform did not cause any
disease (Fig. 3A), indicating that the small number of amino acid changes in meq can
indeed attenuate the virus. Surprisingly, an increase in disease was observed in animals
infected with vLmeq (Fig. 3A), revealing that the 180-bp insertion in Lmeq enhances the
potency of themeq oncogene. Almost all the chickens infected with vLmeq succumbed
to disease (96%), while a lower incidence was observed for wild-type virus (84%).
Consistently, contact animals infected via the natural route with vLmeq had a signiﬁ-
cantly higher disease incidence (45%) compared to the wild-type control (9%). No
pathogenicity was observed in the vSmeq contact animals (Fig. 3C). We conﬁrmed the
increased disease incidence caused by vLmeq in a second independent animal exper-
iment (Fig. 3E).
In addition, we quantiﬁed the number of animals that developed macroscopic
tumors. Remarkably, the virus harboring the Lmeq showed the highest tumor incidence
FIG 2 Replication of recombinant viruses in vivo. MDV genome copies were detected in blood samples of (A) chickens infected
with indicated viruses as well as in (B) contact chickens infected via the natural route by qPCR. Genome copy numbers were
not statistically different (P  0.05, Kruskal-Wallis test).
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(88%) compared to wild-type virus (76%) (Fig. 3B), while no tumors were present in the
vSmeq group (Fig. 3B). In line with this, an increase in the tumor incidence was also
observed in vLmeq contact chickens (64%) compared to the wild-type virus group
(45%) (Fig. 3D). In the case of vSmeq, none of the contact animals developed tumors,
conﬁrming the data from the experimentally infected animals (Fig. 3D). This increased
tumor incidence was conﬁrmed by an independent animal experiment (Fig. 3F).
Intriguingly, tumor dissemination was also enhanced in vLmeq-infected chickens as
more organs harbored tumor lesions per animal (Fig. 4A), highlighting the high
oncogenic potential of the Lmeq isoform.
Role of CVI-meq isoforms in vTR expression. To provide a possible mechanistic
explanation for the increased oncogenic potential of the Lmeq isoform, we examined
the expression of vTR in cells infected with the wild type, vSmeq, and vLmeq using
RT-qPCR. Remarkably, the Lmeq isoform signiﬁcantly upregulated vTR by 12-fold com-
pared to the already highly expressed RB-1B-carriedmeq and Smeq, suggesting that the
180-bp insertion in the transactivation domain strongly inﬂuences vTR expression and
in turn transformation efﬁciency in chickens (Fig. 4B). The increase in vTR copies
thereby provides a reasonable explanation for the increased tumor-promoting activity
of the Lmeq isoform in chickens.
FIG 3 In vivo characterization of recombinant viruses. Kaplan-Meier analyses of Marek’s disease incidence
in chickens infected with indicated recombinant viruses (A and E) and naive chickens infected via the
respiratory route (C) in two independent animal experiments. Statistical analyses using the log-rank test
revealed a signiﬁcant difference between vLmeq and vSmeq in panels A (P  0.0001) and C (P  0.0142).
A signiﬁcant difference between vLmeq and wild type was observed in panels C (P  0.0142) and E (P 
0.02). Tumor incidences are shown as percentage per group in infected chickens (B and F) and in naive
contact chickens (D). Asterisks indicate signiﬁcant differences (*, P 0.05, and **, P  0.0125, Fisher’s exact
test). ns, not signiﬁcant.
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The CVI vaccine is the current “gold standard” vaccine against MDV and efﬁciently
protects against very virulent MDV strains. In previous studies, we and others observed
that at least two meq isoforms are expressed in vaccine stocks (7, 17, 18). The two
predominant meq isoforms expressed from the vaccine are Smeq and Lmeq and were
considered weak oncogenes due to that fact that the CVI vaccine does not induce
tumors. These two meq isoforms differ by an insertion of 180 bp in the transactivation
domain (Lmeq) compared to the Smeq. Both isoforms are only expressed in the CVI
vaccine and have not been detected in other MDV strains, such as RB-1B and MD5 (17).
In this study, we individually delineated the contribution to attenuation and the
oncogenic potential of Smeq and Lmeq.
First, we performed growth kinetics and plaque assays to determine if the insertion
of Smeq and Lmeq affects growth properties, as the oncogene is also expressed during
lytic replication. Our results show that replacing the original meq of the very virulent
RB-1B strain with the CVI-meq isoforms does not signiﬁcantly inﬂuence its growth
properties in vitro (Fig. 1B and C). Furthermore, we could demonstrate that the meq
gene expression of vSmeq or vLmeq was comparable to its counterpart in the wild-type
virus (Fig. 1D), conﬁrming that the observed effects in this study are not due to
differences in the meq expression levels.
Next, we characterized the recombinant viruses in vivo and found that insertion of
Smeq completely abrogated MDV pathogenesis and oncogenesis. The inserted Smeq
only differs by three amino acid changes compared to the wild-type meq from the very
virulent RB-1B MDV strain. It is intriguing that this small number of amino acid changes
in meq could completely attenuate the very virulent RB-1B strain. In contrast, patho-
genesis and oncogenesis were severely enhanced upon insertion of Lmeq. It is remark-
able that an insertion of only 180 bp in the PRR of Smeq drastically enhanced disease
incidence (Fig. 3A) and tumorigenesis (Fig. 3B and 4A) in infected animals. The same
trend was observed in contact chickens that were infected via a natural route. All
recombinant viruses were able to spread efﬁciently to contact chickens (Fig. 2B). We
observed a slight delay with vLmeq; however, this was not statistically signiﬁcant. Only
wild-type and vLmeq viruses were able to cause disease (Fig. 3C) and tumors (Fig. 3D)
in the contact chickens. An independent animal experiment using a different chicken
line conﬁrmed the markedly elevated disease incidence (Fig. 3E) and the high onco-
genic potential of vLmeq (Fig. 3F).
To explain the in vivo data, we focused on a viral gene that (i) plays a role in
transformation and (ii) is regulated by the Meq protein. It has previously been shown
that the Meq protein modulates the expression levels of vTR, which plays a crucial role
in MDV-induced lymphomagenesis and tumor dissemination via cellular c-myc (11, 12,
19). We quantiﬁed the expression levels of vTR in cells infected with the respective
viruses and could show that expression of the Lmeq isoform signiﬁcantly upregulates
vTR compared to the wild-type meq and Smeq. This suggests that the 180-bp insertion
FIG 4 Analysis of tumor dissemination and vTR expression of recombinant viruses. (A) Mean number of
organs with gross tumors per animal in the indicated groups (1st animal experiment). Signiﬁcant
differences are indicated by asterisks (*, P 0.05, and **, P 0.0125, Fisher’s exact test). (B) Mean
genome copies of vTR for the indicated viruses are shown relative to the cellular GAPDH (*, P 0.05,
Kruskal-Wallis test; n 3). ns, not signiﬁcant.
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in the transactivation domain of Lmeq strongly inﬂuences vTR expression via c-myc
(Fig. 4B), and could therefore explain the increased tumorigenesis observed in chickens
infected with vLmeq in both animal experiments.
In addition, our data on Lmeq suggest that other mutations in the CVI genome
contribute to attenuation of the vaccine, resulting in a fully attenuated virus despite the
presence of this potent oncogene. Strikingly, CVI harbors a number of mutations/indels
and amino acid changes compared to virulent strains as published previously (16);
however, whether these changes have an effect on oncogenesis remains elusive. An
alternative explanation for the apathogenic nature of CVI would be that the oncogenic
potential of Lmeq is masked by heterodimerization with the Smeq isoform. It remains
unknown if Smeq and Lmeq can repress each other, an aspect that will be addressed in
future studies. In previous studies, coexpression of CVI Smeq or Lmeq with the onco-
gene of the MD5 strain resulted in a suppression of the meq promoter (7, 20). However,
this suppressive effect was not observed in cells infected with our recombinant viruses
expressing Smeq and Lmeq individually (Fig. 1D).
In summary, we assessed the contribution of the CVI-meq isoforms to the attenua-
tion of the vaccine strain. Our study revealed that the two CVI-meq isoforms allow
efﬁcient virus replication; however, they vastly differ in their tumor-promoting prop-
erties. Strikingly, the Lmeq isoform enhances MDV pathogenesis and oncogenesis of a
very virulent MDV strain, while insertion of the Smeq isoform completely abrogated
MDV pathogenesis. Our results from the Lmeq isoform break with the long-standing
assumption that it is a marker for attenuation (21–23) and demonstrate that other
mutations in the CVI genome contribute to its attenuation.
MATERIALS AND METHODS
Cells. Primary chicken embryo cells (CECs) were prepared from 11-day-old speciﬁc-pathogen-free
(SPF) chicken embryos (Valo BioMedia, Germany) as described previously (24). Cells were cultured in
Eagle’s minimal essential medium (MEM) supplemented with 10% bovine serum and antibiotics (100
U/ml penicillin and 100 g/ml streptomycin) at 37°C in a humidiﬁed atmosphere containing 5% CO2.
Generation of recombinant viruses. We generated recombinant viruses each harboring either
Smeq or Lmeq (GenBank accession no. AY243333 and AY243338) derived from the commercial CVI988/
Rispens vaccine strain (5). Smeq and Lmeq were inserted into a bacterial artiﬁcial chromosome (BAC) of
the very virulent MDV strain RB-1B, which lacks most of the internal repeat long region (IRL; pRB-1BΔIRL),
which is rapidly restored upon virus reconstitution (25). Therefore, only one copy of the meq region had
to be manipulated by two-step Red-mediated mutagenesis as described previously (26, 27), while the
resulting recombinant virus contained the meq substitution in both loci as conﬁrmed by PCR (25). First,
we deleted the meq gene and then introduced either Smeq (vSmeq) or Lmeq (vLmeq). We conﬁrmed the
BAC clones by RFLP, PCR, and Sanger and Illumina MiSeq sequencing (Illumina’s v3 chemistry for 600-bp
pairedend sequencing) to verify the integrity and the sequence of the entire virus genome. The primers
used for mutagenesis and sequencing are listed in Table 1. All viruses were reconstituted and propagated
on CECs, and stocks were prepared as described previously (25, 28).
Plaque size assays and multistep growth kinetics. The spread and replication of the recombinant
viruses were ﬁrst analyzed by plaque size assays as described previously (29). Brieﬂy, 1 million CECs were
infected with 100 PFU of the recombinant viruses and cells were ﬁxed at 6 days postinfection (dpi).
Images of randomly selected plaques (n 50) were taken, and plaque areas were determined using
Image J software (NIH).
Plaque size data were conﬁrmed by qPCR-based multistep growth kinetics as described previously
(29). Brieﬂy, one million CECs were infected with 100 PFU of the recombinant viruses, and virus
replication was assessed by qPCR over 6 days of infection. Primers and probes speciﬁc for the MDV-
infected cell protein 4 (ICP4) and chicken inducible nitric oxide synthase (iNOS) are shown in Table 1.
Virus genome copies were normalized against the chicken iNOS gene as published previously (30).
RT-qPCR. To ensure that the CVI-meq isoforms are expressed comparable to its counterpart in
wild-type RB-1B, we quantiﬁed the expression levels of the different meqs using RT-qPCR as previously
described (31). Brieﬂy, total RNA was extracted from virus-infected CECs using the RNeasy Plus minikit
(Qiagen) according to the manufacturer’s instructions. The samples were treated with DNase I (Promega),
and cDNA was generated using the High-Capacity cDNA reverse transcription kit (Applied Biosystems).
meq expression levels were normalized to the expression levels of cellular GAPDH (glyceraldehyde-3-
phosphate dehydrogenase). We also used this approach to examine the expression of vTR in cells
infected with the wild type and vSmeq and vLmeq strains by RT-qPCR. The vTR expression levels were
normalized to the expression levels of cellular GAPDH (32). The primers and probes used for qRT-PCR are
shown in Table 1.
In vivo characterization of recombinant viruses. The replication properties, pathogenesis, and
tumorigenesis of the recombinant viruses were assessed in speciﬁc-pathogen free (SPF) chickens as
described previously (31). In the ﬁrst animal experiment, 1-day-old Valo SPF chickens (Valo BioMedia)
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were randomly distributed into three groups. The chickens were infected subcutaneously with 4,000 PFU
of the wild type (n 25), vSmeq (n 25), and vLmeq (n 25). Each group was cohoused with 11
noninfected contact animals to assess the natural transmission of the respective virus from experimen-
tally infected birds. The animal experiment was approved by the Landesamt für Gesundheit und Soziales
in Berlin, Germany (LAGeSo; approval no. G0294-17) and was conducted according to relevant national
and international guidelines for humane use of animals. Animals were monitored daily for clinical
symptoms throughout the 86-day experiment.
The phenotype of the vLmeq was conﬁrmed in a second, independent animal experiment. White
leghorn chickens (Sunrise Farms, Inc., Catskill, NY) were inoculated with 1,000 PFU of either the wild type
(n 16) or vLmeq (n 17). This animal experiment was approved by the Agricultural Animal Care and
Use Committee (AACUC; approval no. [22] 05-23-13b-R). Animals were monitored for clinical symptoms
throughout the 43-day experiment.
To eliminate bias, the examining veterinarian had no knowledge of the viruses in the different
groups. All chickens were humanely euthanized and examined for gross tumor lesions if symptoms
appeared or upon termination of the experiment. DNA was isolated from spleens and tumors to conﬁrm
the sequence of the respective meq gene.
Quantiﬁcation of MDV genome copies in blood samples. The virus load in the blood of infected
animals was analyzed at 4, 7, 10, 14, 21, and 28 dpi and for contact animals at days 21, 28, 35, and 42 by
qPCR as described previously (33). DNA was isolated from whole-blood samples of infected and contact
chickens using the E-Z96 blood DNA kit (OMEGA Biotek, USA) according to the manufacturer’s instruc-
tions. We determined MDV genome copy numbers by qPCR using primers and probes speciﬁc for the
MDV ICP4 as described above.
Statistical analysis. Statistical analysis was performed using Graph-Pad Prism v7 and the SPSS
software (SPSS, Inc.). Analysis for plaque size assays and growth kinetics included one-way analysis of
variance (ANOVA). Fisher’s exact test and Kaplan-Meier survival analysis along with the log-rank test
(Mantel-Cox test) were used for analyses of the animal experiment data with Bonferroni correction on
multiple comparisons. Differences were considered signiﬁcant if P was 0.0125.
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ICP4 (qPCR) for CGTGTTTTCCGGCATGTG
rev TCCCATACCAATCCTCATCCA
Probe FAM-CCCCCACCAGGTGCAGGCA-TAM
iNOS (qPCR) for GAGTGGTTTAAGGAGTTGGATCTGA
rev TTCCAGACCTCCCACCTCAA
Probe FAM- CTCTGCCTGCTGTTGCCAACATGC-TAM
meq (RT-qPCR for TTGTCATGAGCCAGTTTGCCCTAT
rev AGGGAGGTGGAGGAGTGCAAAT
Probe GGTGACCCTTGGACTGCTTACCATGC








afor, forward primer; rev, reverse primer.
bFAM, 6-carboxyﬂuorescein; TAM, TAMRA.
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